Lactose (India) (524202)

Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let's take a cold look at Lactose (India). It's a small pharmaceutical company with a ₹223 Cr market cap, trading at ₹172.70. The sales growth of 28% and profit explosion of 141% are exciting, but I don't buy excitement alone. The latest quarter tells me to be cautious: sales of ₹37 Cr but net profit of only ₹1 Cr is a razor-thin margin. The trailing P/E of 24.89 and P/B of 4.16 are rich for a business with 9.39% ROE. In Graham's framework, a single-digit ROE does not justify paying more than four times book unless you see a durable moat and years of compounding ahead. I don't see a clear moat from these figures. There is no dividend, so all returns must come from price appreciation, which depends on growth continuing. The F-Score of 7/9 is encouraging, but debt-to-equity is not available and promoter holding is unknown. I find it difficult to trust what I cannot measure. On the positive side, the PEG of 0.29 implies the market's valuation is not crazy if earnings can sustain high growth. A 28% sales increase gives some evidence of demand. But one year's numbers, especially from a small base, are not enough for a durable conclusion. I would wait for proof of margin resilience, more quarters of profitable growth, and a clearer capital structure before considering investment. At ₹172.70, near the top of its 52-week range against a low of ₹76.01, the market already knows the good news. My job is to pay a reasonable price for quality, and here I think the margin of safety is thin.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer